Author/Authors :
Gibson، نويسنده , , Sheila J and Lindh، نويسنده , , Jana M and Riter، نويسنده , , Tony R and Gleason، نويسنده , , Raymond M and Rogers، نويسنده , , Lisa M and Fuller، نويسنده , , Ashley E and Oesterich، نويسنده , , JoAnn L and Gorden، نويسنده , , Keith B and Qiu، نويسنده , , Xiaohong and McKane، نويسنده , , Scott W and Noelle، نويسنده , , Randy J and Miller، نويسنده , , Richard L and Kedl، نويسنده , , Ross M and Fitzgerald-Bocarsly، نويسنده , , Patricia and Tomai، نويسنده , , Mark A and Vasilakos، نويسنده , , John P، نويسنده ,
Abstract :
The immune response modifiers, imiquimod and resiquimod, are TLR7 agonists that induce type I interferon in numerous species, including humans. Recently, it was shown that plasmacytoid dendritic cells (pDC) are the primary interferon-producing cells in the blood in response to viral infections. Here, we characterize the activation of human pDC with the TLR7 agonists imiquimod and resiquimod. Results indicate that imiquimod and resiquimod induce IFN-α and IFN-ω from purified pDC, and pDC are the principle IFN-producing cells in the blood. Resiquimod-stimulated pDC also produce a number of other cytokines including TNF-α and IP-10. Resiquimod enhances co-stimulatory marker expression, CCR7 expression, and pDC viability. Resiquimod was compared throughout the study to the pDC survival factors, IL-3 and IFN-α; resiquimod more effectively matures pDC than either IL-3 or IFN-α alone. These results demonstrate that imidazoquinoline molecules directly induce pDC maturation as determined by cytokine induction, CCR7 and co-stimulatory marker expression and prolonging viability.
Keywords :
TLR7 , Immune response modifier , PDC , IFN , TLR , DC2 , Plasmacytoid DC , Toll